Suppr超能文献

贲门失弛缓症气囊扩张术5年以上的长期疗效

Long term results of pneumatic dilation in achalasia followed for more than 5 years.

作者信息

West R L, Hirsch D P, Bartelsman J F W M, de Borst J, Ferwerda G, Tytgat G N J, Boeckxstaens G E

机构信息

Department of Gastroenterology, Academic Medical Center, University of Amsterdam, The Netherlands.

出版信息

Am J Gastroenterol. 2002 Jun;97(6):1346-51. doi: 10.1111/j.1572-0241.2002.05771.x.

Abstract

OBJECTIVE

We aimed to evaluate the long term therapeutic outcome in achalasia patients treated with pneumatic dilation, specifically focusing on those patients treated more than 15 yr ago.

METHODS

All patients treated in our center whose records were available for review were asked to fill out a questionnaire assessing their degree of dysphagia, retrosternal pain, regurgitation, weight loss, and coughing during the night. The number of dilations was collected from the clinical records. The results of the treatment were classified into four different classes (excellent, good, moderate, poor). For those patients who had died, the cause of death was ascertained from the medical records or from the general practitioner.

RESULTS

The questionnaires were distributed to 249 patients, 32 of whom had died. Of the 125 patients who completed the questionnaire, 81 (45 male and 36 female) were treated more than 5 yr ago. The mean follow-up was 12+/-1 yr. The therapeutic success rate was 50%, obtained after a median of four dilations (interquartile range = 3-6). Of this cohort, 25 patients (18 male and seven female, aged 35-84 yr) were treated more than 15 yr ago (mean follow-up = 20.5+/-0.5 yr). The median number of dilations was four (interquartile range = 3-7), with a therapeutic success rate of 40%. Two patients experienced a perforation, and seven were referred for surgery. Six patients out of 32 (19%) died of esophageal cancer.

CONCLUSIONS

The long term success rate of pneumatic dilation is rather low, resulting in permanent successful treatment of achalasia in only 40-50% of patients. Achalasia is a risk factor for esophageal cancer.

摘要

目的

我们旨在评估接受气囊扩张治疗的贲门失弛缓症患者的长期治疗效果,尤其关注那些在15年多以前接受治疗的患者。

方法

要求我们中心所有有记录可供查阅的接受治疗的患者填写一份问卷,评估他们吞咽困难、胸骨后疼痛、反流、体重减轻及夜间咳嗽的程度。从临床记录中收集扩张次数。治疗结果分为四个不同等级(优、良、中、差)。对于那些已经死亡的患者,从病历或全科医生处确定死亡原因。

结果

向249例患者发放了问卷,其中32例已经死亡。在125例完成问卷的患者中,81例(45例男性和36例女性)在5年多以前接受了治疗。平均随访时间为12±1年。治疗成功率为50%,在中位数为4次扩张后获得(四分位间距 = 3 - 6)。在这个队列中,25例患者(18例男性和7例女性,年龄35 - 84岁)在15年多以前接受了治疗(平均随访时间 = 20.5±0.5年)。扩张次数的中位数为4次(四分位间距 = 3 - 7),治疗成功率为40%。2例患者发生穿孔,7例被转诊接受手术。32例患者中有6例(19%)死于食管癌。

结论

气囊扩张的长期成功率相当低,仅40% - 50%的患者能获得贲门失弛缓症的永久性成功治疗。贲门失弛缓症是食管癌的一个危险因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验